Protara Therapeutics, Inc.

NasdaqGM:TARA Lagerbericht

Marktkapitalisierung: US$276.5m

Protara Therapeutics Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Protara Therapeutics hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-29.9%

Rückkaufsrendite

Gesamte Aktionärsrendite-29.9%
Zukünftige Dividendenrenditen/a
Wachstum der Dividenden/a
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Ausschüttungsquoten/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Seeking Alpha • Dec 04

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Summary Protara Therapeutics maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002’s 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones without near-term dilution risk. I maintain a 'Buy' rating on TARA, though with tempered conviction, as positive data and market opportunity are balanced by evolving competition and volatility. Read the full article on Seeking Alpha
Analyseartikel • Jul 10

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Mar 28

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Summary TARA’s leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA’s pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives. I also believe their cash reserves and recent raise secure their runway, at least until 2027. So, even though TARA remains a relatively speculative microcap, I believe it trades at a compelling valuation in light of its potential. So I rate it a “Buy” at these levels. Read the full article on Seeking Alpha
Analyseartikel • Mar 07

We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 10

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Summary Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025. Dosing of first patients in phase 3 THRIVE-3 study, using IV choline chloride for parenteral support patients, are expected in Q1 of 2025. The company had $81.5 million in cash as of September 30th of 2024; Despite the cash runway, management chose to raise approximately $100 million through an underwritten public offering. Read the full article on Seeking Alpha
Analyseartikel • Nov 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Protara Therapeutics...
Analyseartikel • Aug 08

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Feb 22

Protara: A Bombed Out Biotech With A Very Positive Skew

Summary Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas. The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is trading below its cash value, presenting a potential undervaluation opportunity if its phase 2 trials are successful. Read the full article on Seeking Alpha
Analyseartikel • Dec 16

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Apr 22

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

The Prognosis For Protara Therapeutics

Summary We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. The stock has seen some small insider buying throughout 2022 and the shares sell for less than 50% of the company's net cash on the balance sheet. An investment analysis follows in the paragraphs below. Men are never convinced of your reasons, of your sincerity, of the seriousness of your sufferings, except by your death. So long as you are alive, your case is doubtful; you have a right only to their skepticism.”― Albert Camus We took our first look at Protara Therapeutics (TARA) back in the first quarter of 2021. No one on Seeking Alpha has provided coverage on the company since. Given I get an occasional question around Protara, today we are going to circle back on this small biopharma concern. An updated analysis follows below. Seeking Alpha Company Overview: Protara Therapeutics was formed when Proteon Therapeutics merged with privately held ArTara Therapeutics in late 2019. The company is based in New York City and is focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. The stock currently trades around $3.50 a share and has an approximate market capitalization of $40 million. March Company Presentation The company's pipeline consists mainly of one key compound in development. Protara's lead pipeline asset is TARA-002. It is in development for the treatment of lymphatic malformations [LMs] and non-muscle invasive bladder cancer (NMIBC). It has a Rare Pediatric Disease designation for LMs. March Company Presentation The company received preliminary guidance regarding a development path for TARA-002 in lymphatic malformations in the first quarter of this year from the FDA. March Company Presentation Management's plan is to initiate a Phase 2 clinical trial in this indication, subject to alignment with FDA on the clinical trial protocol. LMs are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth. March Company Presentation The first patient was dosed in Phase 1 trial evaluating TARA-002 to treat NMIBC in the first quarter of 2022. NMIBC represents 80% of all bladder cancer, which is the sixth most frequent time of cancer in the world. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. March Company Presentation When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan. March Company Presentation The company is also doing a prospective study to enhance its understanding of the incidence of Intestinal Failure Associated Liver Disease or IFALD in patients dependent on parenteral nutrition that remains ongoing. The company did get a key patent for this potential IV Choline Chloride program in April of this year. This candidate is an investigational, intravenous (IV) phospholipid substrate replacement therapy. There doesn't seem to be much movement in this program since we last looked at Protara in February of 2021. March Company Presentation Analyst Commentary & Balance Sheet: The company gets sparse commentary on Wall Street. In 2022, Oppenheimer ($32 price target), H.C. Wainwright ($23 price target) and Ladenberg Thalmann ($32 price target) have maintained Buy ratings on the stock. These are the only analyst firms I can find that have chimed in around Protara so far this year. Approximately two percent of the outstanding float in the shares are currently held short. At the end of the second quarter, the company had nearly $100 million of cash and marketable securities on its balance sheet against no long term debt. Management has guided that this cash balance is sufficient to fund all planned activities until mid-2024. The company had a net loss of $8.5 million in 2Q2022.
Analyseartikel • Sep 12

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Mar 21

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Dec 06

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von TARA in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von TARA gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Protara Therapeutics Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von TARA im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (TARA)n/a
Untere 25 % des Marktes (US)1.4%
Markt Top 25 % (US)4.2%
Branchendurchschnitt (Biotechs)2.4%
Analystenprognose (TARA) (bis zu 3 Jahre)n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von TARA im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von TARA im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von TARA, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da TARA keine Ausschüttungen gemeldet hat.

Entdecken Sie dividendenstarke Unternehmen

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/24 02:41
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Protara Therapeutics, Inc. wird von 10 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.